Analyst Ratings February 11, 2026

Benchmark Affirms Buy on Tesla as Automaker Shifts to an Investment Year

Research firm keeps $475 price target while Tesla accelerates spending across autonomy, AI, robotics and energy

By Marcus Reed TSLA
Benchmark Affirms Buy on Tesla as Automaker Shifts to an Investment Year
TSLA

Benchmark reiterated its Buy rating and $475.00 price target on Tesla (NASDAQ:TSLA) as the company moves into a strategic transition in early 2026, prioritizing reinvestment and platform development over near-term earnings optimization. The firm notes resilient fourth-quarter performance and a strong balance sheet, even as Tesla trades at a high P/E and is judged overvalued against Fair Value by InvestingPro. Additional company developments include large-scale solar capacity plans, an AI training center in China, and corporate governance and SpaceX-related updates.

Key Points

  • Benchmark reiterated a Buy rating on Tesla with a $475.00 price target, implying about 11% upside from a $426.46 share price; analyst targets range from $125 to $600.
  • Tesla is prioritizing reinvestment and platform development in 2026, increasing spending on autonomy, AI, robotics and energy infrastructure while remaining profitable on $94.83 billion in revenue and $3.79 billion in trailing net income.
  • Company fundamentals show strong liquidity and cash generation - more cash than debt and a current ratio of 2.16 - yet valuation is elevated with a P/E of 361 and InvestingPro assessing the stock as overvalued versus Fair Value.

Benchmark has reaffirmed its Buy rating on Tesla (NASDAQ:TSLA) and left its price target unchanged at $475.00 as the electric vehicle maker embarks on a strategic transition expected to take place in early 2026. The $475.00 target implies roughly an 11% upside from the current share price of $426.46, though analyst price objectives on the stock vary considerably, spanning from $125 to $600.

The research firm described Tesla as prioritizing reinvestment and platform development rather than maximizing short-term earnings. That stance accompanies valuation metrics that suggest a stretched equity multiple: Tesla trades at a price-to-earnings ratio of 361. InvestingPro data cited by the research house indicates the share price is overvalued relative to its Fair Value.

Benchmark pointed to Tesla’s fourth-quarter results as evidence of operational resilience during the company’s transition. The firm noted sustained margins, growth in its energy business, and continued cash generation. On the balance sheet, Tesla is reported to have more cash than debt and a current ratio of 2.16. The company’s gross profit margin was recorded at 18.03%.

Calling 2026 an "investment year," Benchmark expects Tesla to accelerate spending across several strategic areas, specifically autonomy, artificial intelligence, robotics, and energy infrastructure. Even as investment increases, the company remains profitable: Tesla generated $3.79 billion in net income over the last twelve months on sales of $94.83 billion.

Benchmark reiterated its valuation framework for Tesla, noting that any near-term share price moves may be shaped by technicals and investor sentiment, while long-term value creation is tied to the company’s transformation into a "physical AI, software, and fleet-based platform rather than a traditional auto OEM." The firm also highlighted Tesla’s size and market behavior, with a market capitalization of $1.6 trillion and a beta of 1.89, reflecting volatility typical of growth-oriented technology companies.


Other items of corporate news and industry developments involving Tesla were also reported. The company announced a sizable expansion in solar manufacturing capacity, targeting an additional 100 GW, a move Benchmark framed as consistent with CEO Elon Musk’s stated vision for solar-powered data centers in space. Morgan Stanley separately reiterated an Equalweight rating on Tesla with a $415 price target.

In China, Tesla has opened an artificial intelligence training center aimed at improving local driving applications and assisted driving capabilities; the center’s launch was confirmed by Tesla Vice President Tao Lin. Additional disclosures noted in public filings and releases include emails from the U.S. Justice Department that link Tesla director Kimbal Musk to two women through interactions with Jeffrey Epstein. The documents, dated from 2012 to 2015, detail exchanges between Musk and Epstein regarding social gatherings and introductions.

Finally, related corporate activity was reported for SpaceX. The company, also founded by Elon Musk, is preparing for a potential initial public offering by engaging with non-US banks, expanding its financial outreach ahead of any such transaction.

For readers seeking more in-depth analysis of Tesla’s financials and long-term growth prospects, Benchmark’s commentary points to additional resources available through InvestingPro, including a Pro Research Report that examines the company’s metrics and strategic outlook.

Risks

  • High valuation - Tesla's P/E of 361 and InvestingPro's assessment that the stock is overvalued introduce the risk of downside if investor sentiment weakens, impacting equity markets and growth-focused technology and automotive sectors.
  • Near-term earnings pressure - the firm's characterization of 2026 as an investment year with accelerated spending could weigh on short-term profitability, affecting investors focused on near-term auto OEM earnings and capital-intensive energy projects.
  • Reputational and governance uncertainty - disclosures linking a director to historical emails involving Jeffrey Epstein may create legal or reputational questions that could influence shareholder perception and trading activity in the stock.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026